PL3411484T3 - Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego - Google Patents
Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowegoInfo
- Publication number
- PL3411484T3 PL3411484T3 PL17747935.9T PL17747935T PL3411484T3 PL 3411484 T3 PL3411484 T3 PL 3411484T3 PL 17747935 T PL17747935 T PL 17747935T PL 3411484 T3 PL3411484 T3 PL 3411484T3
- Authority
- PL
- Poland
- Prior art keywords
- adenosatellite
- virus
- complementary
- threaded
- injection
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 210000004556 brain Anatomy 0.000 title 1
- 239000012530 fluid Substances 0.000 title 1
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292157P | 2016-02-05 | 2016-02-05 | |
| PCT/US2017/014914 WO2017136202A1 (en) | 2016-02-05 | 2017-01-25 | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3411484T3 true PL3411484T3 (pl) | 2024-02-19 |
Family
ID=59500060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17747935.9T PL3411484T3 (pl) | 2016-02-05 | 2017-01-25 | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12070510B2 (pl) |
| EP (2) | EP3411484B1 (pl) |
| JP (4) | JP2019504888A (pl) |
| AU (1) | AU2017214283B2 (pl) |
| DK (1) | DK3411484T3 (pl) |
| ES (1) | ES2962860T3 (pl) |
| FI (1) | FI3411484T3 (pl) |
| HR (1) | HRP20231451T1 (pl) |
| HU (1) | HUE064408T2 (pl) |
| IL (2) | IL300254B2 (pl) |
| LT (1) | LT3411484T (pl) |
| PL (1) | PL3411484T3 (pl) |
| PT (1) | PT3411484T (pl) |
| SI (1) | SI3411484T1 (pl) |
| WO (1) | WO2017136202A1 (pl) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3988660B1 (en) | 2009-05-02 | 2025-05-14 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
| CA2912678C (en) | 2013-05-15 | 2023-10-10 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| KR20170096998A (ko) | 2014-11-05 | 2017-08-25 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드 |
| WO2016077689A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| HRP20231451T1 (hr) | 2016-02-05 | 2024-03-01 | Emory University | Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu |
| IL305449B1 (en) | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Gene therapy for the treatment of mucocutaneous type ii diabetes |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| JP2019531787A (ja) | 2016-08-30 | 2019-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム |
| WO2018089527A1 (en) | 2016-11-09 | 2018-05-17 | Intrexon Corporation | Frataxin expression constructs |
| WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| SG11202002457RA (en) | 2017-09-22 | 2020-04-29 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| KR102709597B1 (ko) | 2017-10-03 | 2024-09-26 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애를 위한 유전자 요법 |
| AU2018346102B2 (en) | 2017-10-03 | 2023-05-11 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| IL273776B2 (en) | 2017-10-03 | 2025-06-01 | Prevail Therapeutics Inc | Gene therapies for lysosomal disorders |
| WO2019152843A1 (en) | 2018-02-01 | 2019-08-08 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
| JP2021523914A (ja) | 2018-05-15 | 2021-09-09 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | パーキンソン病を治療するための組成物および方法 |
| IL280198B1 (en) * | 2018-07-18 | 2025-09-01 | Regenxbio Inc | Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus) |
| EP3856913A4 (en) | 2018-09-26 | 2022-10-26 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| JP7528066B2 (ja) | 2018-09-28 | 2024-08-05 | ボイジャー セラピューティクス インコーポレイテッド | 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法 |
| CN113227126A (zh) * | 2018-11-26 | 2021-08-06 | 巴塞罗那自治大学 | 成纤维细胞生长因子21(fgf21)基因治疗 |
| MX2021009404A (es) * | 2019-02-04 | 2021-11-12 | Res Inst Nationwide Childrens Hospital | Administracion del virus adenoasociado de polinucleotido de cln6. |
| KR20210145180A (ko) * | 2019-03-21 | 2021-12-01 | 피티씨 테라퓨틱스, 인크. | 엔젤만 증후군을 치료하기 위한 벡터 및 방법 |
| AU2020270984B2 (en) | 2019-04-10 | 2025-11-20 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| CA3136004A1 (en) | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| CN114430684A (zh) * | 2019-04-12 | 2022-05-03 | 编码治疗公司 | 用于治疗剂投予的组成物及方法 |
| JP2022528010A (ja) * | 2019-04-12 | 2022-06-07 | ユニバーシティ オブ マサチューセッツ | メープルシロップ尿症（ｍｓｕｄ）のａａｖ媒介遺伝子治療 |
| KR20220128632A (ko) * | 2019-12-31 | 2022-09-21 | 스완바이오 테라퓨틱스 리미티드 | 개선된 aav-abcd1 구축물 및 부신백질이영양증 (ald) 및/또는 부신척수신경병증 (amn)의 치료 또는 예방을 위한 용도 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| EP4171658A4 (en) * | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | Modified viral compositions for viral transduction |
| WO2021263060A2 (en) * | 2020-06-24 | 2021-12-30 | Lycia Therapeutics, Inc. | Bifunctional bridging compositions for viral transduction |
| IL303239A (en) * | 2020-12-01 | 2023-07-01 | Univ Pennsylvania | Compositions and their uses for the treatment of Engelmann syndrome |
| AU2022214429A1 (en) | 2021-02-01 | 2023-09-14 | Tern Therapeutics, Llc | Gene therapy for neuronal ceroid lipofuscinoses |
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス， インコーポレイテッド | Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US6110743A (en) | 1995-02-10 | 2000-08-29 | The Regents Of The University Of California | Development and use of human pancreatic cell lines |
| AU4645697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| WO1999061601A2 (en) | 1998-05-28 | 1999-12-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav5 vector and uses thereof |
| DK1127150T3 (da) | 1998-11-05 | 2007-09-24 | Univ Pennsylvania | Nucleinsyresekvenser fra det adeno-associerede virus af serotype 1 samt vektorer og værtsceller, der indeholder disse |
| DE69941905D1 (de) | 1998-11-10 | 2010-02-25 | Univ North Carolina | Virusvektoren und verfahren für ihre herstellung und verabreichung. |
| JP4827353B2 (ja) | 1999-08-09 | 2011-11-30 | ターゲティッド ジェネティクス コーポレイション | 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大 |
| WO2001092551A2 (en) | 2000-06-01 | 2001-12-06 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| US9056048B2 (en) * | 2001-08-16 | 2015-06-16 | The Trustees Of The University Of Pennsylvania | Synthesis and use of cationic steroids for anti-inflammatory drug therapy |
| EP1453837A4 (en) * | 2001-11-21 | 2007-11-07 | Activbiotics Inc | TARGETED THERAPEUTIC AGENTS AND USES THEREOF |
| JP4559429B2 (ja) | 2003-05-21 | 2010-10-06 | ジェンザイム・コーポレーション | 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法 |
| EP3910063A1 (en) | 2003-09-30 | 2021-11-17 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP2019143A1 (en) | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
| AU2009209408B2 (en) | 2008-01-29 | 2015-06-11 | Beacon Therapeutics Limited | Recombinant virus production using mammalian cells in suspension |
| WO2010114948A2 (en) | 2009-04-02 | 2010-10-07 | University Of Florida Research Foundation, Inc. | An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors |
| US8692332B2 (en) | 2010-01-14 | 2014-04-08 | United Microelectronics Corp. | Strained-silicon transistor and method of making the same |
| WO2011094198A1 (en) | 2010-01-28 | 2011-08-04 | The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
| US10392632B2 (en) | 2011-02-14 | 2019-08-27 | The Children's Hospital Of Philadelphia | AAV8 vector with enhanced functional activity and methods of use thereof |
| US20150182637A1 (en) | 2012-06-21 | 2015-07-02 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
| PT2879719T (pt) * | 2012-08-01 | 2018-10-08 | Ohio State Innovation Foundation | Administração intratecal do vírus adeno-associado 9 recombinante |
| AU2013388083B2 (en) * | 2013-05-01 | 2019-08-22 | Genzyme Corporation | Compositions and methods for treating spinal muscular atrophy |
| MX2017009336A (es) * | 2015-01-16 | 2017-11-15 | Voyager Therapeutics Inc | Polinucleótidos dirigidos al sistema nervioso central. |
| HRP20231451T1 (hr) | 2016-02-05 | 2024-03-01 | Emory University | Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu |
-
2017
- 2017-01-25 HR HRP20231451TT patent/HRP20231451T1/hr unknown
- 2017-01-25 HU HUE17747935A patent/HUE064408T2/hu unknown
- 2017-01-25 WO PCT/US2017/014914 patent/WO2017136202A1/en not_active Ceased
- 2017-01-25 PL PL17747935.9T patent/PL3411484T3/pl unknown
- 2017-01-25 PT PT177479359T patent/PT3411484T/pt unknown
- 2017-01-25 AU AU2017214283A patent/AU2017214283B2/en active Active
- 2017-01-25 FI FIEP17747935.9T patent/FI3411484T3/fi active
- 2017-01-25 IL IL300254A patent/IL300254B2/en unknown
- 2017-01-25 SI SI201731434T patent/SI3411484T1/sl unknown
- 2017-01-25 ES ES17747935T patent/ES2962860T3/es active Active
- 2017-01-25 EP EP17747935.9A patent/EP3411484B1/en active Active
- 2017-01-25 JP JP2018560432A patent/JP2019504888A/ja not_active Withdrawn
- 2017-01-25 EP EP23194145.1A patent/EP4299079A3/en not_active Withdrawn
- 2017-01-25 LT LTEPPCT/US2017/014914T patent/LT3411484T/lt unknown
- 2017-01-25 DK DK17747935.9T patent/DK3411484T3/da active
- 2017-01-25 US US16/075,122 patent/US12070510B2/en active Active
-
2018
- 2018-08-02 IL IL260954A patent/IL260954B2/en unknown
-
2022
- 2022-04-22 JP JP2022070524A patent/JP2022101648A/ja active Pending
-
2023
- 2023-11-07 US US18/504,029 patent/US20240108761A1/en not_active Abandoned
-
2024
- 2024-04-03 JP JP2024059869A patent/JP2024084797A/ja active Pending
- 2024-07-12 US US18/771,234 patent/US20250135041A1/en active Pending
- 2024-12-26 JP JP2024230721A patent/JP2025041933A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4299079A3 (en) | 2024-05-01 |
| AU2017214283B2 (en) | 2023-06-29 |
| IL300254B1 (en) | 2025-02-01 |
| AU2017214283A1 (en) | 2018-08-02 |
| HRP20231451T1 (hr) | 2024-03-01 |
| DK3411484T3 (da) | 2023-11-20 |
| JP2025041933A (ja) | 2025-03-26 |
| US20250135041A1 (en) | 2025-05-01 |
| WO2017136202A1 (en) | 2017-08-10 |
| HUE064408T2 (hu) | 2024-03-28 |
| IL300254A (en) | 2023-03-01 |
| IL260954A (pl) | 2018-09-20 |
| IL300254B2 (en) | 2025-06-01 |
| ES2962860T3 (es) | 2024-03-21 |
| EP3411484B1 (en) | 2023-10-04 |
| US12070510B2 (en) | 2024-08-27 |
| CA3012653A1 (en) | 2017-08-10 |
| PT3411484T (pt) | 2023-11-17 |
| JP2019504888A (ja) | 2019-02-21 |
| LT3411484T (lt) | 2023-11-27 |
| EP3411484A4 (en) | 2019-08-07 |
| SI3411484T1 (sl) | 2023-12-29 |
| US20240108761A1 (en) | 2024-04-04 |
| JP2022101648A (ja) | 2022-07-06 |
| EP4299079A2 (en) | 2024-01-03 |
| IL260954B2 (en) | 2023-07-01 |
| EP3411484A1 (en) | 2018-12-12 |
| FI3411484T3 (fi) | 2023-11-15 |
| IL260954B1 (en) | 2023-03-01 |
| JP2024084797A (ja) | 2024-06-25 |
| US20190038777A1 (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3411484T3 (pl) | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego | |
| EP3360554A4 (en) | AGGREGATE AGAINST HEPATITIS B VIRUS | |
| EP3430731A4 (en) | IUGW ARCHITECTURE | |
| EP3464313A4 (en) | MODIFIED NUCLEOTIDES 5 '-CYCLO-PHOSPHONATE | |
| EP3689215A4 (en) | REGIONAL ATTRIBUTE DETERMINATION | |
| MA45192A (fr) | Traitement d'association | |
| MA46180A (fr) | Analogues de l'amyline | |
| EP3360118A4 (en) | Flow alarm | |
| EP3592232A4 (en) | STEERABLE GUIDE CATHETER | |
| EP3500943A4 (en) | FINGERPRINT LAYOUTS FOR FINGERPRINTING CONTENT | |
| MA46717A (fr) | Variantes de l'endonucléase homing tcra | |
| MA43873A (fr) | Dspositif d'injection | |
| EP3378606A4 (en) | AUXILIARY SET | |
| ITUB20153015A1 (it) | Dispositivo per l'infusione di fluidi | |
| EP3291722A4 (en) | IMPROVED LENS OPPORTER | |
| FR3055905B1 (fr) | Methode de sexage precoce d'esturgeon | |
| EP3415524A4 (en) | INHIBITOR OF α-SYNNUCLEINE EXPRESSION | |
| EP3525841A4 (en) | MICRO DELIVERY DEVICE | |
| EP3322451A4 (en) | ELECTROCHEMICAL REDUCTION OR PREVENTING INFECTIONS | |
| EP3431808A4 (en) | BUFFER STOPPER | |
| EP3365793A4 (en) | AUTHORIZING I / O COMMANDS WITH I / O TOKENS | |
| EP3332319A4 (en) | FILTERING WRITE COMMANDS | |
| EP3444345A4 (en) | MicroRNA-143 DERIVATIVE | |
| EP3433782A4 (en) | INTEGRATED INTERACTIVE APPLICATION SAFETY TESTING | |
| MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 |